Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Hematol., Transfus. Cell Ther. (Impr.) ; 42(3): 269-274, July-Sept. 2020. ilus
Artículo en Inglés | LILACS | ID: biblio-1134046

RESUMEN

ABSTRACT Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD)1 in parallel with the increase availability of novel therapy agents.In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHV status) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed.2,3


Asunto(s)
Leucemia Linfocítica Crónica de Células B/diagnóstico , Genes p53 , Neoplasia Residual , Citometría de Flujo , Mutación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA